The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors.


Journal Article (Review)

Cerebrospinal fluid (CSF) may be the best hope for minimally invasive diagnosis and treatment monitoring of central nervous system (CNS) malignancies. Discovery/validation of cell-free nucleic acid and protein biomarkers has the potential to revolutionize CNS cancer care, paving the way for presurgical evaluation, earlier detection of recurrence, and the selection of targeted therapies. While detection of mutations, changes in RNA and miRNA expression, epigenetic alterations, and elevations of protein levels have been detected in the CSF of patients with CNS tumors, most of these biomarkers remain unvalidated. In this review, we focus on the molecular changes that have been identified in a variety of CNS tumors and profile the approaches used to detect these alterations in clinical samples. We further emphasize the importance of systemic collection of CSF and the establishment of standardized collection protocols that will lead to better cross-study biomarker validation and hopefully FDA-approved clinical markers.

Full Text

Duke Authors

Cited Authors

  • Mattox, AK; Yan, H; Bettegowda, C

Published Date

  • December 17, 2019

Published In

Volume / Issue

  • 21 / 12

Start / End Page

  • 1509 - 1518

PubMed ID

  • 31595305

Pubmed Central ID

  • 31595305

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

Digital Object Identifier (DOI)

  • 10.1093/neuonc/noz156


  • eng

Conference Location

  • England